



# **Texas Medicaid Vendor Drug Program Drug Utilization Review Board Meeting**

July 26, 2019



# Revised Criteria: Acetylcholinesterase Inhibitors

- Dosage
  - Monotherapy/combination therapy separated into two tables (Tables 1 and 2)
- References - updated



# Revised Criteria: COX-2 Inhibitors

- ▶ Dosage
  - ▶ Combination therapy discussed in general statement
  - ▶ Adults
    - ▶ Added combination therapy table (Table 2)
      - ▶ Celecoxib/amlodipine (Consensi)
- ▶ Duration of Therapy
  - ▶ Added celecoxib/amlodipine to general section statement
- ▶ Drug-Drug Interactions
  - ▶ Added amlodipine/celecoxib interactions with:
    - ▶ Clopidogrel
    - ▶ CYP3A4 inducers/inhibitors
    - ▶ Simvastatin
    - ▶ Tacrolimus
- ▶ References - updated



# Revised Criteria: Hepatitis C Direct-Acting Antivirals

- ▶ Dosage

- ▶ Adults

- ▶ Added new agents and/or updated treatment indications for Tables 1 and 2
    - ▶ Added adjunctive therapy for Tables 1 and 2
    - ▶ Added new agents and adjunctive therapy, updated treatment indications for Tables 3 and 4
      - ▶ Monotherapy
        - ▶ Sofosbuvir (Sovaldi®)
      - ▶ Combination Therapy
        - ▶ Elbasvir/grazoprevir (Zepatier®)
        - ▶ Glecaprevir/pibrentasvir (Mavyret™)
        - ▶ Ledipasvir/sofosbuvir (Harvoni®)
          - ▶ Added generics
        - ▶ Sofosbuvir/velpatasvir (Epclusa®)



# Revised Criteria: Hepatitis C Direct-Acting Antivirals - *continued*

- ▶ Dosage
  - ▶ Pediatrics
    - ▶ Separated as monotherapy and combination therapy (Tables 5 and 6)
    - ▶ Added treatment indications/ adjunctive therapy
    - ▶ Added pediatric indication for glecaprevir/pibrentasvir (Mavyret™)
    - ▶ Added generics for ledipasvir/sofosbuvir (Harvoni®)
- ▶ Duration of Therapy
  - ▶ Updated table numbers
  - ▶ Adults
    - ▶ Updated duration information for Genotypes 1, 1a, and 1b
      - ▶ Patients without baseline NS5A resistance polymorphisms
        - ▶ elbasvir/ grazoprevir (Zepatier®)



# Revised Criteria: Hepatitis C Direct-Acting Antivirals - *continued*

- ▶ Duration of Therapy
  - ▶ Pediatrics
    - ▶ Added therapy duration for glecaprevir/pibrentasvir (Mavyret™)
- ▶ Duplicative Therapy
  - ▶ Updated wording
- ▶ Drug-Drug Interactions
  - ▶ Table number updated
- ▶ References - updated



# Revised Criteria: Histamine 2 Receptor Antagonists (H2RAs)

- ▶ Dosage

- ▶ Adults


- ▶ Updated acute/maintenance tables (Tables 1 and 2)- monotherapy

- ▶ Added heavy smoker dosing recommendations for cimetidine

- ▶ Updated H2RA *Helicobacter pylori* recommendations from American College of Gastroenterology

- ▶ Pediatrics

- ▶ Updated indications, ages, recommended dosages for acute/maintenance therapy – Tables 3, 4



# Revised Criteria: Histamine 2 Receptor Antagonists (H2RAs) - *continued*

- ▶ Duration of Therapy
  - ▶ Updated Table numbers
- ▶ Drug-Drug Interactions
  - ▶ Updated pH-dependent drugs for solubility interaction – added erlotinib (Tarceva®), modified significance level)
- ▶ References - updated





# Revised Criteria: Ketorolac

- References - updated
- 



# Revised Criteria: Leukotriene Receptor Antagonists

- ▶ Dosage
  - ▶ Pediatrics
    - ▶ Updated asthma montelukast dosages for :
      - ▶ Children 2-5 years of age
      - ▶ Children 12-23 months of age
- ▶ Drug-Drug Interactions
  - ▶ Added ergot alkaloids to zafirlukast-CYP3A4 interaction
  - ▶ Added zafirlukast-saquinavir interaction
- ▶ References - updated



# Revised Criteria: Mecasermin

- References - updated
- 



# Revised Criteria: Memantine

- ▶ Dosage
  - ▶ Adults
    - ▶ Separated monotherapy/combination therapy tables (Tables 1 and 2)
    - ▶ Updated general wording in dosage statement (added systematic review reference)
- ▶ Drug-Drug Interactions
  - ▶ Updated table number
- ▶ References - updated